Core Viewpoint - Canopy Growth has significantly underperformed in the cannabis industry, losing 99% of its value over the past five years, with shares trading under $2, making it unattractive for investment [1][11]. Financial Performance - Canopy Growth reported a net revenue of 65 million Canadian dollars for Q4 of fiscal year 2025, down 11% year-over-year, despite a 4% increase in cannabis revenue in Canada [6]. - The company remains deeply unprofitable, with a net loss per share of CA$1.43, worsening from a CA$1.03 loss per share in the previous year [7]. Market Challenges - The cannabis market is heavily regulated, leading to stiff competition and oversupply issues, particularly in Canada and the U.S., where cannabis remains illegal at the federal level [4][10]. - Canopy Growth's international operations, including its subsidiary Storz & Bickel, have not mitigated the negative impact on overall performance [2][6]. Management Outlook - Management has attempted to present a positive outlook by highlighting a 49% reduction in total debt during fiscal year 2025 and aims to achieve positive adjusted EBITDA in the "near term" [8][9]. - Despite potential long-term opportunities in the U.S. cannabis market, the vague nature of management's goals raises skepticism about the company's future profitability [8][9]. Investment Sentiment - The current lack of revenue growth and the uncertain regulatory environment in the U.S. contribute to the view that Canopy Growth is not an attractive investment option [10][11].

Group 1: Company Overview - Tilray Brands went public in 2018 and has since faced significant challenges, with the stock losing nearly all its value despite the U.S. cannabis market exceeding $38 billion last year [1][2] - The company has evolved into a global cannabis business, initially focusing on medical cannabis and later expanding into recreational cannabis, hemp foods, and beverages [4][5] - Tilray currently sells over 40 brands of cannabis products and generated $829 million in sales last year, with projected revenue growth to $893 million this year and $943 million next year [5][6] Group 2: Financial Performance - While sales are not a concern, Tilray has struggled with profitability, reporting a free cash flow of minus $92 million and net losses nearing $250 million last year [7][8] - The U.S. cannabis market is expected to grow over 11% annually through 2030, presenting opportunities for Tilray's diverse product portfolio [6] Group 3: Challenges and Risks - The company has faced operational challenges due to varying legal statuses of cannabis across states in the U.S., leading to pricing pressures and competition from the black market [8] - Tilray's rapid expansion has resulted in a 348% increase in diluted share count since 2018, which negatively impacts revenue and profit distribution among shareholders [9][10] - Despite potential future growth, the stock is unlikely to yield significant returns for investors due to ongoing losses and share dilution [11]

As filed with the U.S. Securities and Exchange Commission on October 18, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FLORA GROWTH CORP. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Ontario, Canada 2833 Not Applicable (I.R.S. Employer Identification No.) 3406 SW ...